JP7895041B2 - Flna結合化合物及びその塩酸塩の固体多形 - Google Patents

Flna結合化合物及びその塩酸塩の固体多形

Info

Publication number
JP7895041B2
JP7895041B2 JP2021549470A JP2021549470A JP7895041B2 JP 7895041 B2 JP7895041 B2 JP 7895041B2 JP 2021549470 A JP2021549470 A JP 2021549470A JP 2021549470 A JP2021549470 A JP 2021549470A JP 7895041 B2 JP7895041 B2 JP 7895041B2
Authority
JP
Japan
Prior art keywords
peaks
ray powder
powder diffraction
xrpd
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523196A (ja
JP2022523196A5 (cg-RX-API-DMAC10.html
Inventor
マイケル ザムルート
リンジィ バーンズ バービアー
ショーン アンソニー クセラ
Original Assignee
フィラナ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィラナ セラピューティクス インコーポレイテッド filed Critical フィラナ セラピューティクス インコーポレイテッド
Publication of JP2022523196A publication Critical patent/JP2022523196A/ja
Publication of JP2022523196A5 publication Critical patent/JP2022523196A5/ja
Priority to JP2024005868A priority Critical patent/JP2024054139A/ja
Application granted granted Critical
Publication of JP7895041B2 publication Critical patent/JP7895041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021549470A 2019-02-21 2020-02-21 Flna結合化合物及びその塩酸塩の固体多形 Active JP7895041B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024005868A JP2024054139A (ja) 2019-02-21 2024-01-18 Flna結合化合物及びその塩酸塩の固体多形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808609P 2019-02-21 2019-02-21
US62/808,609 2019-02-21
PCT/US2020/019305 WO2020172584A1 (en) 2019-02-21 2020-02-21 Solid polymorphs of a flna-binding compound and its hydrochloride salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005868A Division JP2024054139A (ja) 2019-02-21 2024-01-18 Flna結合化合物及びその塩酸塩の固体多形

Publications (3)

Publication Number Publication Date
JP2022523196A JP2022523196A (ja) 2022-04-21
JP2022523196A5 JP2022523196A5 (cg-RX-API-DMAC10.html) 2023-02-07
JP7895041B2 true JP7895041B2 (ja) 2026-07-27

Family

ID=72141575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549470A Active JP7895041B2 (ja) 2019-02-21 2020-02-21 Flna結合化合物及びその塩酸塩の固体多形
JP2024005868A Pending JP2024054139A (ja) 2019-02-21 2024-01-18 Flna結合化合物及びその塩酸塩の固体多形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024005868A Pending JP2024054139A (ja) 2019-02-21 2024-01-18 Flna結合化合物及びその塩酸塩の固体多形

Country Status (10)

Country Link
US (4) US11370791B2 (cg-RX-API-DMAC10.html)
EP (1) EP3927707A4 (cg-RX-API-DMAC10.html)
JP (2) JP7895041B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210135530A (cg-RX-API-DMAC10.html)
CN (2) CN120004896A (cg-RX-API-DMAC10.html)
AU (1) AU2020224678B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016622A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131146A1 (cg-RX-API-DMAC10.html)
IL (1) IL285763A (cg-RX-API-DMAC10.html)
WO (1) WO2020172584A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882428B1 (en) 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
JP7895041B2 (ja) 2019-02-21 2026-07-27 フィラナ セラピューティクス インコーポレイテッド Flna結合化合物及びその塩酸塩の固体多形
WO2022098700A1 (en) * 2020-11-03 2022-05-12 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) * 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
EP2488177B1 (en) * 2008-10-31 2016-10-12 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
WO2011119559A1 (en) * 2010-03-25 2011-09-29 Schering Corporation Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
EP2882428B1 (en) * 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
JP7895041B2 (ja) 2019-02-21 2026-07-27 フィラナ セラピューティクス インコーポレイテッド Flna結合化合物及びその塩酸塩の固体多形

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明編著、有機化合物結晶作製ハンドブック -原理とノウハウ-、丸善株式会社、平成20年7月25日、pp.17-23、37-40、45-51、57-65
芦澤一英編著、医薬品の多形現象と晶析の科学、丸善プラネット株式会社、2002年9月20日、pp.273、278、305-17

Also Published As

Publication number Publication date
US20250084083A1 (en) 2025-03-13
CN114072406B (zh) 2025-03-18
BR112021016622A2 (pt) 2021-11-03
US20220340574A1 (en) 2022-10-27
US12391693B2 (en) 2025-08-19
JP2022523196A (ja) 2022-04-21
EP3927707A1 (en) 2021-12-29
IL285763A (en) 2021-10-31
CN114072406A (zh) 2022-02-18
US20200270250A1 (en) 2020-08-27
CN120004896A (zh) 2025-05-16
US11370791B2 (en) 2022-06-28
WO2020172584A1 (en) 2020-08-27
KR20210135530A (ko) 2021-11-15
AU2020224678B2 (en) 2024-03-14
US12065440B2 (en) 2024-08-20
CA3131146A1 (en) 2020-08-27
EP3927707A4 (en) 2022-11-09
NZ779310A (en) 2024-01-26
US20240400566A1 (en) 2024-12-05
JP2024054139A (ja) 2024-04-16
AU2020224678A1 (en) 2021-09-16

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230130

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260622

R150 Certificate of patent or registration of utility model

Ref document number: 7895041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150